Total Voting Rights

RNS Number : 0653I

Oxford Biomedica PLC

28 June 2013

 

For Immediate Release

28 June 2013

Oxford BioMedica plc ("the Company")

Total Voting Rights Update

In accordance with the FCA's Disclosure and Transparency Rules, Oxford BioMedica plc (LSE:OXB) confirms that the Company's issued share capital consists of 1,416,149,005 ordinary shares of 1p each, all with voting rights.  No shares are held in treasury.

This figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Nomura Code Securities Juliet Thompson/Jonathan Senior/Christopher Golden	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

TVREAKKXAEEDEFF